Chapter Twenty-Six - New Chemical Entities Entering Phase III Trials in 2013

• Autores: Gregory T. Notte
• Localización: Annual reports in medicinal chemistry, ISSN 0065-7743, Vol 49, 2014, págs. 417-436
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Abstract This year's JOURter of New Chemical Entities Entering Phase III Trials provides an overview of novel synthetic organic molecules entering Phase III clinical trials in the United States. From the 1390, Phase III trials registered at ClinicalTrials.gov in 2013 classified as having a “drug intervention,” 43 compounds met the selection criteria for inclusion (e.g., synthetic in origin, first time reaching Phase III for any indication, structure available). This information serves as a quick reference for those wishing to track the progress of drug candidates as they move closer to approval and complements the information provided in JOURter 27. A brief summary of the molecules described in previous year's JOURters is included along with an analysis of their current development status.